Doherty, Teodora
Wajs, Ewa
Melkote, Rama
Miller, Janice
Singh, Jaskaran B.
Weber, Michael A.
Funding for this research was provided by:
Janssen Research and Development, LLC, Titusville, NJ, USA
Article History
First Online: 29 January 2020
Compliance with Ethical Standards
:
: The open access fee was paid by Janssen Research & Development, LLC, Titusville, NJ, USA, which also provided funding for the studies reported in this article.
: Teodora Doherty, Ewa Wajs, Rama Melkote, and Janice Miller are employees of Janssen Research & Development, LLC and hold company equity. Michael A. Weber is a consultant with Janssen Pharmaceuticals. Jaskaran B. Singh worked on the clinical development program of esketamine for treatment-resistant depression during his employment by Janssen Research & Development, LLC; he is currently employed by Neurocrine Biosciences, San Diego, CA USA.
: All authors provided their consent for publication of this article.
: The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at ExternalRef removed. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at ExternalRef removed.
: An Institutional Review Board (IRB) (USA) or Independent Ethics Committee (IEC) (Europe) approved the study protocols and their amendments. All procedures performed in the studies were in accordance with the ethical standards of the IRB/IEC and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the studies.